

Regeneron Ventures Invests in Cell Therapy Company ArsenalBio

Client News

September 4, 2024

Gunderson Dettmer represented client Regeneron Ventures in participating in the \$325 million Series C financing of Arsenal Biosciences (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors. ArsenalBio is aiming to build the industry's largest DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features. The new capital will be used to advance ArsenalBio's lead programs through development as the company continues to build its pipeline of therapeutic candidates and to drive further innovation in developing tools and processes for identifying new candidate cell therapies.

In the [announcement of the transaction](#), ArsenalBio co-founder, CEO and chairman Ken Drazan, M.D. said, "Our initial clinical trials and preclinical studies have shown the promise of our T cell engineering approach and have given us the confidence to broaden the application of our technology to address additional cancer types. This new investment enables us to continue our development roadmap, scale up our manufacturing capabilities, and invest in new avenues for innovation in T cell medicine."

The Gunderson Dettmer deal team was led by Jeff Engerman and included Tim Kulis.

Companies

[Regeneron Ventures](#)

[Arsenal Biosciences](#)

Related People



Jeffrey M. Engerman

PARTNER

P +1 617 648 9175

Timothy J. Kulis

COUNSEL

P +1 617 648 9236

Related Services

Fund Investments in Companies

Late-Stage Company

Life Sciences

Private & Public Companies

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)